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The correlation between high exhaled nitric oxide levels and eosinophilic-mediated airway inflammation in 
patients with atopic asthma has been well documented. This generates prerequisites that a regulatory feedback 
mechanism exists between them. Therefore, the paper briefly describes evidence implementing biosynthesis, 
enzyme structural features, expression regulation of its isoforms and effects of nitric oxide, which have helped 
elucidate molecular mechanisms by which nitric oxide selectively promotes asthma exacerbation. In previous 
study we have demonstrated that airway infiltrate of immune cells contributes to NO synthesis in the respira-
tory tract during allergic inflammation under guinea pig model of acute asthma with multiple challenges. On 
the basis of these findings the authors posits that nitric oxide represents an additional signal of the induction of 
Th2 subset response and be considerably involved in the complex network of immune regulation distinctive 
for atopic asthma phenotype.
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Introduction
Asthma is a chronic inflammation of the airways that 
involves airflow obstruction and increased airway 
responsiveness to a variety of stimuli, which leads to 
the symptoms of recurrent coughing and dyspnea [1]. 
Albeit the understanding of disease pathogenesis has 
progressed enormously in the last several decades 
[1–3], asthma is still a major public health problem, 
affecting 300 million people worldwide and rapidly 
increasing in all age groups [4, 5]. Clinically, several 
distinct phenotypes are recognized, but the therapy 
and research have been basically focused on allergic 
(atopic) asthma [1–3].
Currently, the routine asthma treatment relies on 
suppressing the inflammation (glucocorticoids, leu-
kotriene inhibitors as additional medication) as well 
as removal of bronchoconstriction (β agonists, anti-
cholinergics) [6, 7]. The symptom-based guidance 
of treatment could predispose to an increased num-
ber of exacerbations. Thus, asthmatics might benefit 
from the inflammatory marker-addressed therapy [1, 
8]. Although many physiologic processes have been 
implicated in asthma pathogenesis, the range of evi-
dence supports the key roles of endogenous nitric 
oxide (NO) and NO-derived reactive nitrogen spe-
cies (RNS) in modulating either a normal airway 
function [8, 9] or inflammation in asthma [10, 11]. 
Therefore, NO has received a tremendous amount of 
attention in the medical community as a selective 
pulmonary disorder marker [8, 12, 13]. 
NO is an ubiquitous messenger that regulates var-
ious biological functions — either at low concentra-
tions as a signal molecule in many physiological 
processes, or at high concentrations as cytotoxic and 
cytostatic defensive mechanisms against tumors and 
pathogens [9, 11]. Also it is thought to be a marker of 
lung inflammation. NO is detected in exhaled breath 
[8, 12, 13]. Fractional exhaled NO (FeNO) levels 
were shown to correlate with sputum eosinophil 
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count, airway hyperresponsiveness, bronchodilator 
response, serum IgE levels, allergen skin prick test-
ing, asthma symptoms, and lung function. This led 
to the general belief that atopy is associated with 
higher levels of exhaled NO (eNO) [11]. 
From this background, the current article deals 
with the consideration of the source of NO formation 
and its triggers in asthma pathogenesis. We aim to 
discuss the cases, when NO becomes a marker of al-
lergic inflammation. Simultaneously, we present our 
data that revealed the contribution of immune cells 
settling down the airways to the respiratory NO gen-
eration. 
1. Biosynthesis and enzyme structure basis
The role of NO in the human body is under the scope 
of intensive research. NO is generated by oxidation 
of L-arginine; this reaction is typically catalyzed by 
the nitric oxide synthases (NOS) [9] in the presence 
of several co-factors: flavones (FAD, FMN), tetrahy-
drobiopterin (BH4) and NADPH [14]. NOS are ste-
reospecific and active as homodimers [14]. The en-
zyme exists in three isoforms: neuronal NOS (nNOS/
NOS1), inducible NOS (iNOS/NOS2) and endothe-
lial NOS (eNOS/NOS3) [15–18]. 
nNOS and eNOS are constitutively expressed iso-
forms (cNOS) in cells as the preformed proteins that 
are activated in response to the cell-specific stimuli 
through the elevation of intracellular Ca2+ concentra-
tions and the binding of calmodulin. iNOS form is 
generally associated with the immune system and 
produces NO for prolonged periods of time in a cal-
cium-independent manner [9–11, 14–22]. iNOS is 
activated by bacterial lipopolysaccharides and pro-
inflammatory cytokines such as inteleukin-1, TNF-α, 
IFN-γ [15]. However, IFN-γ is the most potent and 
prevailing inducer of iNOS in vivo [23]. As 
T-lymphocytes and NK-cells are the main source of 
IFN-γ production, the iNOS induction is mediated 
by them. The endothelial cell derived factor, endo-
thelin-1 (ET-1), has been shown to promote iNOS 
expression [24, 25]. Ultimately, iNOS incorporates a 
calmodulin binding site to which the calmodulin is 
tightly bound independently of a calcium signal – 
this is thought to be responsible for the continuous 
activity of the enzyme [15–17]. Up to 1000 times 
higher levels of NO can be generated by iNOS com-
pared to cNOS [11, 19]. 
The NOS enzyme functions as a dimer consisting 
of two identical monomers, which can be function-
ally and structurally divided into two major domains: 
a C-terminal reductase domain and an N-terminal 
oxygenase (catalytic) domain. All NOS isoforms are 
members of the cytochrome P450 enzyme group 
owing to the presence of a haem complex [20]. Thus 
the mammalian NOS share similar domain architec-
ture, with an N-terminal catalytic domain containing 
a haem active site, a nearby cofactor site for BH4 
and a C-terminal reductase domain consisting of 
FMN, FAD and NADPH binding sites. We visual-
ized catalytic domain of human NOS enzymes in 
three-dimensional form using PDB files via Cn3D 
viewer from MMDB (Fig. 1). The macromolecular 
3D structures display the evidence, that eNOS and 
iNOS isoforms are very similar in the overall mo-
lecular shape, relative orientation of cofactors and 
stereochemistry within the catalytic centre. As the 
catalytic sites of iNOS and eNOS are so similar it is 
not obvious from a structural starting point how the 
selective inhibitors may be designed [26].
2. Localization of nitric oxide synthase iso-
forms in respiratory tract and its biological 
role
In the respiratory tract all isoforms have been identi-
fied [20, 21]. cNOS-derived NO along with other 
NO adduct molecules are involved in maintaining 
normal metabolic functions, such as airway and pul-
monary vascular tone, intracellular signaling, immu-
nity (platelet aggregation, leukocyte adhesion) and 
neurotransmission [7, 22]. By contrast to this, iNOS-
derived NO seems to play a pro-inflammatory pri-
mary role in the cytokine dependent processes [19]. 
Albeit, agonists such as sheer stress, bradykinin, 
acetylcholine and histamine still may activate cNOS, 
resulting in the release of NO within seconds [20].
eNOS is constitutively expressed in both the en-
dothelial cells of the bronchial and pulmonary circu-
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lation and the alveolar endothelial cells, and airway 
epithelial cells throughout the respiratory tract [27]. 
The traces of NO from eNOS activity have been iso-
lated in the airway epithelium and found to partici-
pate in ciliary movement and mucus ejection [28, 
29]. Although eNOS is present in airway epithelium, 
iNOS is considered to be a predominant form in it 
[19]. The recent evidence has demonstrated a link 
between certain eNOS gene polymorphisms and in-
creased serum IgE levels in patients with allergic 
asthma [30]. Functionally, nNOS mediates neuronal 
bronchodilation in the skeletal muscles and choliner-
gic airway nerves [27]. When allergic asthma was 
being launched, the increased arginase activity at-
tenuates the nNOS-catalyzed synthesis of NO and 
induces neural bronchoconstriction [31]. In this way 
cNOS isoforms reveal an indirect involvement in 
asthma pathophysiology.
In general, iNOS regulates approximately 200 
genes that are relevant to inflammation, infection or 
apoptosis [21]. In the airways iNOS is expressed by 
epithelial and endothelial cells [23, 32], smooth mus-
cle cells [18, 32, 33], lung fibroblasts [34]. In contrast 
to other cell types that do not express NOS2 unless 
induced by cytokines, the NOS2 mRNA expression 
and NOS2 protein were detected in epithelial cells of 
normal, noninflamed upper and lower airways and in 
pulmonary myocytes of large hilar veins by a variety 
of techniques, including Northern blotting, in situ hy-
bridization, Western blotting, and immunohisto-
chemistry [23, 35]. Additionally, iNOS-derived NO 
is produced by the genuine immune-system cells in-
cluding monocytes and macrophages [16, 17, 36], 
eosinophils [37, 38], neutrophils [39, 40], dendritic 
cells [41]. The reports about the NOS expression in 
the mast cell population appear to be ambiguous. The 
data presented in numerous papers clearly indicate 
distinct differences in diversity and localization of 
NOS in a variety of mast cell populations expressed 
in human and rodents [42–44]. Notably, the iNOS ex-
pression and NO generation are up-regulated by the 
antigen stimulation FcɛRI engagement in the differ-
ent subsets of mast cells [44]. Additionally, the NO 
production prevents mitochondrial integrity collapse, 
thereby protecting mast cells against antigen-induced 
apoptosis [45]. Previously several reports have con-
firmed that the rat mast cells produce iNOS mRNA 
and the protein upon treatment [46–48]. However 
subsequent studies have demonstrated that some 
types of human mast cell were positive for eNOS but 
showed variable expression of nNOS and no detect-
able iNOS [42, 43]. Together these findings suggest 
the important differences between the rat and human 
mast cells in the NO production and NO-mediated 
regulation of mast cell function [42]. NK cells ex-
press constitutive eNOS mRNA and protein, howev-
er the levels of iNOS are not detectable. The endog-
enous NO production is involved in protection of NK 
cells from activation of apoptosis induced by CD16 
cross-linking, thereby maintaining NK activity [49]. 
This is the further evidence that, unlike NO produced 
by iNOS, cNOS-derived NO is critical for normal 
physiology.
Farther, the biological effect of NO ultimately de-
pends on its concentration and interaction with other 
bioreactive molecules and proteins [50]. NO can be 
converted to NO2, NO2–, NO3– and other reactive 
nitrogen intermediates (RNI), among which the most 
important are S-nitrosothiols (S-NO), peroxynitrite 
(ONOO–) and nitrosyl-metal complexes, which are 
directly implicated in the RNI-mediated free radical 
reactions (S-nitrosylation of cysteines, nitration of 
tyrosines, and nitrosylation of prosthetic groups, re-
spectively) [51]. In summary, the excessive NO-
adduct molecules namely ONOO–, nitrogen dioxide 
(NO2), dinitrogen trioxide (N2O3), and higher ox-
ides of nitrogen can provoke detrimental post-trans-
lational modifications [13, 50, 52]. 
3. Nitric oxide formation as a marker 
of Th2-mediated infllammation
There is rising evidence for an important immuno-
regulatory role of NO in the development of the 
adaptive immune responses associated with autoim-
mune and allergic diseases. Increased levels of ex-
haled NO [53–56] along with an up-regulation of 
iNOS in asthmatic airways [57] confirm that this 
radical should be involved in asthma. It has been 
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demonstrated, that, in humans, a higher than normal 
NO concentration in exhaled breath is closely asso-
ciated with the enlarged transcriptional activation of 
NOS2 gene [58]. 
Nevertheless, the previous studies, using murine 
and guinea pig models of asthma and iNOS inhibitor 
treatment or iNOS-deficient animals, have generated 
controversial results. In two different studies, iNOS 
deficiency [59] or iNOS inhibitor treatment [60] had 
no effect on the lung inflammation, whereas in other 
study the airway inflammation was inhibited in the 
iNOS deficient mice [61]. Such a discrepancy was 
attributed to significant differences in the immuniza-
tion and challenge protocols [59].
Further investigations have shown that inhibited 
iNOS activity correlates with a decrease of nitroty-
rosine and, more importantly, ameliorates FEV1 and 
airway responsiveness to histamine [14]. However, 
the different subgroups analysis of atopic individu-
als now suggests that it is the inflammation in atopic 
individuals with clinical manifestations of airway 
disease, rather than atopy itself, that accounts for the 
increased production of NO by iNOS [62]. eNO was 
commonly regarded qua a marker of eosinophilic in-
flammation [63–65]. In addition, the 2011 American 
Thoracic Society (ATS) guideline for the use of 
FeNO in clinical practice characterized FeNO as an 
indicator of eosinophilic airway inflammation [12]. 
However, the recent studies have indicated that 
FeNO is more representative of a Th2-driven local 
inflammation, specifically of the bronchial mucosa, 
rather than general eosinophilic inflammation, as 
measured by blood or induced sputum [66]. The dis-
connect between FeNO and eosinophilic inflamma-
tion has been highlighted by two separate studies 
with monoclonal antibodies (mAb) against IL-5 and 
IL-13, which indicate that treatment with mepoli-
zumab, an anti-IL-5 mAb, significantly reduces 
blood and sputum eosinophils without affecting 
FeNO levels [67] whereas treatment with lebriki-
zumab, an anti-IL-13 mAb, significantly reduces 
FeNO levels without reducing blood eosinophils 
[68]. Another research has shown that, in asthmatic 
children but not in controls, eNO levels and BAL 
fluid eosinophil percentages correlate well regard-
less of the methods used to measure eNO [69]. Thus, 
eNO levels interconnect better with bronchial eo-
sinophils than with sputum eosinophils.
Based on the findings of the bronchoalveolar la-
vage fluid (BALF) studies and the lung tissue histo-
logical analysis, the mechanisms for late allergic re-
sponsiveness (LAR) are considered to be causally 
related to the infiltration of eosinophils and other 
inflammatory cells into the bronchial mucosa [70]. It 
has been suggested that NO play an important role in 
LAR [10, 71]. In the airways of asthmatic patients 
[57] or in rodent lung after allergen challenge [61, 
72], iNOS expression and/or enzymatic activity are 
increased. 
To give insight into the role of nitrosative stress 
established by immune cells infiltrating the airways 
we examined the NO formation in BAL cells under 
the guinea pig model of acute ovalbumin (OVA)-
induced asthma with repeated challenges following 
32 weeks after sensitization [73]. This model mimics 
those seen in humans exposed to an allergen a long 
period after acquired hypersensitivity. A suggested 
protocol reflects the allergen-driven pathway of 
asthma reproducing several characteristic features, 
such as airways infiltration by inflammatory cells, 
early allergic responsiveness (EAR) and LAR, AHR. 
Flow cytometry analysis using DAF-2DA dye 
showed, that multiple allergen challenge exposures 
of sensitized guinea pigs were associated with an ex-
cessive level of the intracellular NO generation in 
BAL cells (Figure 2). Hence, OVA aerosol provoca-
tions of guinea pigs with sensitization resulted in a 
substantial growth of BAL cells containing NO in 
comparison with sensitized group (33.50[27.80–
45.80] % versus 6.30[2.20–7.82] %; p=0.0001). Our 
results are in line with the data confirming that al-
lergic inflammation is accompanied by NO. 
Moreover, there is apparent evidence that iNOS in-
hibition, during the challenge period, markedly re-
duced the development of the inflammatory process 
in the OVA-induced murine model after allergen 
challenge through down-regulation of chemokine 
expression [74].
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Taking into account that BAL explores large ar-
eas of the alveolar compartment providing cellular 
constituents from the lower respiratory tract, we 
identified the alterations in cellular composition of 
BAL as indicated in FACS density graphs (Fig. 3). 
OVA provocations in sensitized animals were 
shown to cause a strong inflammation in lungs. 
This led to the redistribution of immune subpopula-
Fig. 1. The structures of oxygenase do-
main of human NOS isoforms. 
A – dimeric unit of eNOS haem domain 
with L-arginine bound (PBD ID:4D1O). 
B – tetrameric unit of nNOS haem domain 
with L-arginine bound (PBD ID: 4D1N). 
C – tetrameric unit of iNOS with Zn-bound 
and L-arginine complex (PBD ID: 1NSI). 
The enzyme structures show a ball and 
stick backbone in a trace shape, no side 
chains to alignment protein views, and sol-
id objects – condensed lines and massive 
cylinders with arrows – to represent strands 
and helices. The arrows on helix cylinders 
point in the N-to-C direction. The extent of 
each monomer element in macromolecule 
is designated by color (blue, violet, green 
and brown). Haem, BH4 and arginine, 
glycerol are shown in a tube representation. 
The association into a dimer involves a 
large interface, which includes the binding 
site for BH4 and helps to structure the ac-
tive-site pocket containing the haem and 
the L-arginine binding site
Fig. 2. NO content in BAL cells 18–20 h after induction of allergic lung inflammation: morphological flow cytometric parameters of 
cell types concerning size (FS) and granularity (SS). Panel A: BAL cells derived from sensitized guinea pigs with allergen chal-
lenges (II coumn) display augment of NO generation compared to sensitized animals (I column). Panel B: fractions of BAL cells 
incorporating NO from two compared groups (I and II columns) are also demonstrated in the individual dot plots. Green-colored cells 
include NO molecules (adopted from [73] and supplemented in this paper)
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tions in the general pool of cells infiltrating respira-
tory tract. 
In addition to quantitative assessment of NO for-
mation, the allocation of intracellular NO content in 
BAL suspension was analyzed depending on the size 
and granularity (Fig. 4, Fig. 5) [73].
In view of these findings we infer that in asthma, 
due to increased iNOS protein expression and ac-
tivity, the excessive NO generation is activated in 
lung tissue cells (mainly airway epithelial cells), 
but also in multi-cellular airway infiltrate recruited 
to trigger organ during allergic inflammation. High 
BAL levels of NO may reflect circulating nitrosa-
tive stress in respiratory tract, when exacerbation in 
asthma is present. Indeed inhibition of iNOS-de-
rived NO attenuates antigen-induced airway con-
striction, inflammatory, and reduces collagen and 
elastic fiber deposition in a guinea pig model of al-
lergic asthma [37]. 
4. Immunoregulatory cross-talk of nitric 
oxide in asthma pathogenesis
The network of molecules involved in the allergic 
inflammatory processes becomes more complex 
since NO derivatives have been demonstrated to 
play a role in these reactions. The allergic disorder 
pathogenesis is modulated by NO at the level of im-
mune system [20, 32]. In turn, iNOS transcription is 
regulated by a number of pathways, including the 
JNK, JAK-STAT, and p38 MAPK pathways, which 
are largely activated through the cytokine induction 
Fig. 3. Distinction of BAL cellular compostion of sensitized 
guinea pigs (I column) compared to sensitized animals, that re-
ceived allergen challenges (II column). Subpopulation content 
and ratio in BAL suspensions based on the morphological flow 
cytometric parameters side scatter (SS) versus forward scatter 
(FS) are illustrated in density plots
Fig. 4. NO formation as a function of cellular size in BALF sub-
populations derived from OVA sensitized guinea pigs (I column) 
and OVA sensitized animals treated with OVA aerosol exposures 
(II column). DAF-2DA stained cells are colored in green (ad-
opted from [73] and supplemented here)
Fig. 5. NO generation in accordance with the complexity of 
BALF cell subpopulations of OVA sensitized guinea pigs (I col-
umn) and of OVA sensitized animals treated with OVA aerosol 
exposures (II column). DAF-2DA stained cells are colored in 
green (adopted from [73] and supplemented here)
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[75]. In allergic asthma the immune response to in-
haled antigens results from the activation of mast 
cells and antigen-specific Th2 cells, followed by the 
production of cytokines, including interleukin IL-4, 
IL-5 and IL-13 [3]. Further, IL-4 and IL-13 cause 
lung epithelial expression of iNOS to be upregulated 
via STAT-6, a process which is corticosteroid sensi-
tive [76]. Moreover, the group of researchers pro-
vided evidence, that IL-13 robustly induces the ex-
pression of an active dimeric iNOS enzyme in pri-
mary HAEC (human airway epithelial cells) main-
tained in air–liquid interface culture, consistent with 
its expression in relation to Th2 inflammation [77]. 
Therefore, eNO is a direct signal of the Th2-
mediated, pro-inflammatory cytokine mechanisms 
of central importance in the pathophysiology of al-
lergic airway inflammation. At present, there is open 
debate about whether NO exacerbates or reduces au-
toimmune and allergic chronic inflammation. 
The detrimental impact of NO is implemented due 
to its ability to launch a hyperinflammatory response, 
leading to tissue damage. Two mechanisms are pri-
marily responsible for inducing NO-mediated dam-
age: action of NO-induced inflammatory mediators 
and apoptosis of NO-targeted cells. NO modulates 
the production and function of cytokines released by 
immune cells, chemokines, and growth factors [78]. 
NO-mediated apoptosis represents one of the key 
factors contributing to enhanced inflammation and 
tissue damage during noninfectious respiratory dis-
eases, such as asthma [79]. The recent study has re-
vealed that NO induces eosinophil apoptosis in a 
mechanism mediated via ROS, JNK, and later mito-
chondrial permeability transition [80]. 
iNOS-derived NO plays an immunomodulatory 
role, as it may shift the Th1/Th2 balance in favor of 
Th2, thus promoting IgE-mediated allergy [75, 81]. 
Th1 cells secrete IFN-γ, TNF-α, and IL-2 and pro-
mote cellular immune responses against intracellular 
antigens, whereas Th2 cells secrete IL-4, IL-5, IL-
10, and IL-13, induce IgG1- and IgE-mediated hu-
moral responses, and are important for the elimina-
tion of large extracellular parasites such as helmin-
thes and nematodes [82]. The molecular mechanisms 
of Th1 versus Th2 regulation rely on the counterbal-
ance between expression of the IL-12 receptor β2-
chain (IL-12Rβ2)
3 on Th1 cells and GATA-3 tran-
scription in Th2 cells. IL-4 induced GATA-3 allows 
the stable commitment to the Th2 phenotype through 
promotion of Th2 cytokine production, such as IL-4, 
IL-5, IL-10 and IL-13 [83, 84]. IL-10 produced by 
Th2 cells further suppresses the Th1 development by 
inhibiting the secretion of IFN-γ and IL-12 and may 
also directly inhibit the induction of iNOS [81]. 
Moreover, NO markedly inhibits the induction of 
IL-2 promoter, which could account for most of the 
reduction in IL-2 production, and increases the pro-
duction of IL-4 by effector T cells [85]. To conclude, 
NO can inhibit Th1 lymphokines but has no direct 
impact on the Th2 lymphokines production [78, 81]. 
As the continuous expression of iNOS in the normal 
epithelium is maintained mainly by IFN-γ [19, 21, 
23], the present observations indicated that NO se-
lectively inhibits the expansion of Th1 cells by a 
negative feedback mechanism. In contrast, low con-
centrations of NO stimulate T cells to express IL-
12R and promote Th1 differentiation [86].
The counter-evidence of the absence of a direct 
effect of NO on Th2 cells was found since the NO 
donors inhibit the proliferation of Th1 and Th2 pop-
ulations. The NO donors SIN-1 (3-morpholino-syd-
nonimine) and SNAP (S-nitroso-N-acetyl-DL-
penicillamine) suppress the proliferation of anti-
CD3 or mitogen activated human peripheral Th1 and 
Th2 cell clones, and prevent the release of IFN-γ, 
IL-2, IL-4, IL-5 and IL-10 [87]. Additionally it has 
also been reported that NO inclusion to human bron-
chial epithelial cells reversibly inhibits the prolifera-
tion of activated Th1 and Th2 CD4+ T cells in atopic 
asthma [88]. 
IgE-dependent synthesis of NO by various cell 
populations bearing low-affinity IgE receptors 
(FceRII; CD23) implicates in local allergic and in-
flammatory reactions, including macrophages, eo-
sinophils and keratinocytes [89]. NO is also an im-
portant agent in eosinophil migration and infiltra-
tion. Several reports demonstrated that the acute 
treatment with the non-selective inhibitors of NO 
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reduced allergen-induced eosinophilia, showing that 
NO is involved in the inflammatory cell recruitment 
[44, 90, 91]. Furthermore, it has been found that the 
l-NAME (N ω-nitro-l-arginine methyl ester) treat-
ment decreases the number of eosinophils positive 
for both nNOS and iNOS, whereas the treatment 
with 1400W, a highly selective iNOS inhibitor, de-
creases only the iNOS-positive eosinophils, reduc-
ing the eosinophil density in alveolar septa of aller-
gen-sensitized animals [92]. In addition to these 
findings, NO is crucial to the numerous mast cell 
functions, including degranulation, adhesion, and 
protease release, as well as the production and secre-
tion of chemokines and cytokines [42]. NO also con-
trols the processes in immune system through regu-
lation of the chemokine expression. Among the 
asthma pathophysiology processes, involving NO, 
are modulation of the co-stimulatory and adhesion 
molecules, such as VCAM-1 (vascular cell adhesion 
molecule-1), ICAM-1 (intercellular adhesion mole-
cule-1), CD62E (E-selectin) and CD62P (P-selectin), 
synthesis and deposition of the extracellular material 
components via TGF-β [93].
The anti-inflammatory effects of NO may be me-
diated by several mechanisms including the inhibi-
tion of gene expression and the secretion of proin-
flammatory cytokines [94, 95], reduction of the pro-
inflammatory effects of cytokines such as IL-8 
through the covalent modification by nitration of ty-
rosine [96], or by protection against the programmed 
cell death through inactivation of the proteolytic en-
zymes responsible for apoptosis [97, 98]. Thus, the 
endogenous NO synthesis in asthma, may be an im-
portant early physiological defense mechanism 
against the injury and inflammation. Nevertheless, 
persistently elevated levels of the NO formation can 
deepen the tissue injury over time.
Conclusions
The presented evidence posits the nitrosative stress 
as a relevant pathogenic mechanism underlying 
atopic asthma. The diversity of NOS enzymes pro-
duces different profiles of NO activities as well as of 
its derivatives facilitating and broadening the func-
tional versatility of nitrosative events. Many studies 
and clinical observations are bringing to light a mul-
titude of different mechanisms through which NO 
operates in respiratory tract and mediates dysfunc-
tion in the disease. Mounting evidence of a link be-
tween the NO synthesis and the allergic inflamma-
tion raises the possibilities for therapeutic interven-
tion. Two major challenges currently hinder the 
progress towards this aim; on one hand the multi-
plicity of asthma nature with a complex immunoge-
netic basis and a strong environmental contribution; 
on the other hand the likelihood of mimicking the 
full spectrum of responses to the allergen exposures 
and the tested pharmaceuticals by in vivo and in vitro 
models seems fragile. Hence, despite the significant 
advances in our understanding, the effective marker-
addressed therapy strategies and reliable approaches 
for the precise diagnostics and monitoring are cur-
rently still limited.
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Нітрозативні події в патогенезі атопічної астми
О. О. Парилова, Т. Т. Володіна, С. Г. Шандренко
Кореляцію між високим рівнем оксиду азоту, що видихається 
та еозинофіл-опосередкованим запаленням дихальних шляхів 
у пацієнтів з атопічною бронхіальною астмою добре доведено. 
Це створює передумови існування регуляторного механізму 
зворотнього зв’язку між ними. Тому стаття стисло наводить 
свідчення стосовно біосинтезу, структурних особливостей ен-
зиму, регуляції експресії його ізоформ та дії оксиду азоту, що 
допомагає з’ясувати молекулярні механізми завдяки яким 
оксид азоту сприяє загостренню перебігу захворювання. В по-
передній експериментальній роботі ми продемонстрували, що 
інфільтрат імунних клітин, які персистують в дихальних шля-
хах, робить внесок у синтез оксиду азоту в респіраторному 
тракті під час пізньої алергічної реакції за моделі гострої брон-
хіальної астми мурчаків з множинними провокаціями алерге-
ну. На основі цих даних автори констатують, що оксид азоту є 
додатковим сигналом індукції відповіді Th2 ланки та залуче-
ний в складну мережу імунної регуляції, характерної для фено-
типу атопічної астми.
Ключов і   слова: оксид азоту, атопічна астма, синтази 
оксиду азоту, алергічне запалення дихальних шляхів, еозино-
філія.
Нитрозативные события в патогенезе атопической 
астмы
Е. А. Парилова, Т. Т. Володина, С. Г. Шандренко
Корреляция между высоким уровнем оксида азота в выдыхае-
мом воздухе и эозинофил-опосредованным воспалением ды-
хательных путей у пациентов с атопической бронхиальной 
астмой хорошо обоснована. Это порождает предпосылку, что 
существует механизм регулирования обратной связи между 
ними. Таким образом, статья кратко описывает данные касаю-
щиеся биосинтеза, структурных особенностей энзима, регули-
рования экспрессии его изоформ и воздействия оксида азота, 
которые помогают выяснить молекулярные механизмы, благо-
даря чему оксид азота селективно содействует обострению 
астмы. В предыдущей экспериментальной работе мы показа-
ли, что инфильтрат иммунных клеток в дыхательных путях 
дополняет синтез оксида азота в респираторном тракте во вре-
мя аллергического воспаления на модели острой бронхиаль-
ной астмы морских свинок с множественными провокациями 
аллергена. На основании этих данных авторы констатируют, 
что оксид азота представляет собой дополнительный сигнал 
индукции ответа Th2 звена и значительно вовлечен в сложную 
сеть иммунной регуляции, отличительной для фенотипа ато-
пической астмы.
Ключевые  слова: оксид азота, атопическая астма, синта-
зы оксида азота, аллергическое воспаление дыхательных пу-
тей, эозинофилия.
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